Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women

Inclusion Criteria: * The subject must be a lactating female who had a normal full-term pregnancy and has been actively breastfeeding or pumping for at least 4 weeks; lactation must be well established per Investigator discretion. * The subject must be willing to pump regularly during the study to maintain milk supply and discontinue breastfeeding for the entire 13-day Treatment and Washout Periods. * The subject must not be pregnant. * The subject must be surgically sterile or willing to use 1 acceptable method of birth control. Exclusion Criteria: * Has clinically significant infection (e.g., pneumonia, pyelonephritis) or chronic infection within 30 days prior to enrollment. * Has evidence of unstable or uncontrolled, clinically significant cardiovascular, central nervous system, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder, including serious allergy, asthma, hypoxemia, hypertension, seizures, or allergic skin rash, that, in the opinion of the Investigator, would confound the study results or compromise subject safety. * Has estimated glomerular filtration rate (eGFR) \<30 mL/min/1.732 using the Modification of Diet in Renal Disease (MDRD) formula. * Has liver disease or dysfunction characterized by Child-Pugh Class B or Class C. * History of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease. * Has active…